Company: RVRC
Filing Date: 2025-10-03
Form Type: S-1/A
Source: 0001213900-25-096094
Chunk: 62

Company: Revium Rx.
Filing Date: 2025-10-03
Form: S-1/A
Chunk 62
---
 we intend to apply to the OTCQB. Notwithstanding our belief that upon the effective date of this registration statement
our Common Stock will satisfy the admission requirements for the OTCQB and our intention to make application for quotation on the OTCQB
Market, we cannot assure you that our Common Stock will be quoted on the OTCQB tier.

Holders

As of October 3, 2025, there were 118 holders
of record of our Common Stock. The number of record holders does not include an indeterminate number of stockholders whose shares are
held by brokers in street name.

Dividend Policy

We have not paid any dividends since our incorporation
and do not anticipate the payment of dividends in the foreseeable future. At present, our policy is to retain earnings, if any, to develop
and market our products and implement our business plan. The payment of dividends in the future will depend upon, among other factors,
our earnings, capital requirements, and operating financial conditions.

<div align='center'>35

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS OF REVIUM RX. AND REVIUM RX LTD.</div>

The following discussion should be read in conjunction with our consolidated financial statements and notes thereto included herein. We caution readers regarding certain forward-looking statements in the following discussion and elsewhere herein and any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward-looking statements are statements not based on historical information and which relate to future operations, strategies, financial results, or other developments. Forward-looking statements are necessarily based upon estimates and assumptions that are inherently subject to significant business, economic and competitive uncertainties, and contingencies, many of which are beyond our control and many of which, with respect to future business decisions, are subject to change. These uncertainties and contingencies can affect actual results and could cause actual results to differ materially from those expressed in any forward-looking statements made by, or on our behalf. We disclaim any obligation to update forward-looking statements.

Overview and Recent Developments

We are a pre-clinical biopharmaceutical company
that is principally engaged in development of innovative nano-medicines to deliver advanced treatment solutions for diseases with limited
or no effective treatment options. We focus on creating smarter, more targeted treatments that improve how medicines work in the body,
with the goal of increasing effectiveness while reducing side effects. We are developing advanced lipid-based platforms for a variety